Integra LifeSciences (NASDAQ:IART) Sets New 12-Month High – Here’s Why

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $19.07 and last traded at $18.9650, with a volume of 54640 shares. The stock had previously closed at $18.40.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IART. Wall Street Zen upgraded shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Citigroup reiterated a “neutral” rating and set a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. BMO Capital Markets started coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price objective on the stock. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Finally, Argus upgraded Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $18.33.

Integra LifeSciences Price Performance

The business has a 50-day moving average of $16.81 and a two-hundred day moving average of $13.04. The company has a current ratio of 3.38, a quick ratio of 1.95 and a debt-to-equity ratio of 1.75. The firm has a market cap of $1.54 billion, a P/E ratio of -3.07, a price-to-earnings-growth ratio of 1.30 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.41 by $0.13. The firm had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business’s quarterly revenue was up 2.4% on a year-over-year basis. During the same period last year, the company earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds have recently added to or reduced their stakes in the business. Global Retirement Partners LLC acquired a new position in Integra LifeSciences in the 4th quarter valued at approximately $25,000. Osaic Holdings Inc. lifted its holdings in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Integra LifeSciences by 145.9% during the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after purchasing an additional 3,742 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Integra LifeSciences by 595.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock worth $98,000 after purchasing an additional 6,814 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Integra LifeSciences in the fourth quarter valued at $124,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.